Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga DOTA-5G in Metastatic Breast Cancer
NCT07915297Phase 1Not yet recruiting
- Sponsor
- Luminance Biosciences
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]Ga DOTA-5G in breast cancer, sponsored by Luminance Biosciences. Primary endpoint: Ability to detect lesions at 2 hours. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
[68Ga]Ga DOTA-5G
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07915297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915297.